uu.seUppsala universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Neuroprotection by S-PBN in hyperglycemic ischemic brain injury
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Anestesiologi och intensivvård.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Anestesiologi och intensivvård.
2011 (Engelska)Ingår i: Coronary artery disease: 2011 update: Proceedings of the 9th International Congress onCoronary Artery Disease / [ed] Basil S. Lewis, Moshe Y. Fugelman, David A. Halon, Bologna: Medimond, 2011, s. 41-43Konferensbidrag, Publicerat paper (Refereegranskat)
Abstract [en]

Background: Hyperglycemia exacerbates focal ischemic brain damage supposedly through various mechanisms. One such mechanism is oxidative stress involving reactive oxygen and nitrogen species (RONS) production. Nitrones attenuate oxidative stress in various models of brain injury. Sulphonated nitrones are hydrophilic and highly feasible to administer in experimental settings. Sodium 2-sulfophenyl-N-tert-butyl nitrone (S-PBN) has been shown neuroprotective in experimental brain trauma. Together with the theories on increased oxidative stress in focal brain ischemia with concomitant hyperglycemia, we hypothesised that S-PBN might be neuroprotective under those circumstances as well.

Material and methods: The rats were made hyperglycemic by intraperitoneal bolus of glucose (2 g/kg) and then subjected to 90 min transient middle cerebral artery occlusion (MCAO). They were randomised to a therapeutic regime of S-PBN (47 mg/kg) or saline given intravenously. Neurological testing and tetrazolium red staining were performed after 1 day.

Results: S-PBN improved the neurological performance at day 1 both in Bederson score (1,3 +/- 0,8 vs. 2,7 +/- 0,48)(figure 1) and on the inclined plane [74,5% +/- 4,6 (S-PBN) vs. 66% +/- 8,3 (control) P< 0.05] (figure 2); but did not reduce the infarct size (figure 3). Physiological data did not differ between groups (table1).

Ort, förlag, år, upplaga, sidor
Bologna: Medimond, 2011. s. 41-43
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:uu:diva-172309ISI: 000300222000008ISBN: 978-88-7587-619-7 (tryckt)OAI: oai:DiVA.org:uu-172309DiVA, id: diva2:513960
Konferens
9th International Congress on Coronary Artery Disease ICCAD 2011, Venice Italy, October 23-26 2011
Tillgänglig från: 2012-04-04 Skapad: 2012-04-04 Senast uppdaterad: 2012-04-04Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Personposter BETA

Molnar, MariaLennmyr, Fredrik

Sök vidare i DiVA

Av författaren/redaktören
Molnar, MariaLennmyr, Fredrik
Av organisationen
Anestesiologi och intensivvård
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

isbn
urn-nbn

Altmetricpoäng

isbn
urn-nbn
Totalt: 383 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf